Pharmaceuticals
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
- Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of € 50 million with the potential of receiving a further € 400...
2020-10-06 20:00
2906
Results Evaluating The Effect Of Ubiquinol On Endothelial Function Published In Nutrients
PASADENA, Texas, Oct. 6, 2020 /PRNewswire/ -- Kaneka Nutrients today announced the results of an 8-week, randomized, double-blind, single-center trial, demonstrating health benefits of Ubiquinol on endothelial function and antioxidant protection. This study was designed to measure change in flow...
2020-10-06 01:33
2103
Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 30, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II clinical trials of Batoclimab (HBM 9161), a fully human...
2020-09-30 21:50
5189
Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology
STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collabor...
2020-09-30 15:44
2924
Data Science to Accelerate Drug Discovery with Artificial Intelligence and Machine Learning, Says Frost & Sullivan
Pharmaceutical companies and hospitals are adopting data science rapidly, and its application is going to be established in all branches of healthcare SANTA CLARA, Calif., Sept. 29, 2020 /PRNewswire/ -- Frost & Sullivan's recent analysis,Data Science Impacting the Pharmaceutical Industry, finds t...
2020-09-29 22:10
2943
Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic
OSAKA, Japan, Sept. 29, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a ...
2020-09-29 20:01
2559
Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial
SEOUL, South Korea, Sept. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) announced the result of its phase 2 trial on enavogliflozin, a novel SGLT2 inhibitor, for the first time at the 2020 International Congress of Diabetes and Metabolism (ICDM) held on Sep. 18–19. ...
2020-09-29 15:00
1831
Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...
2020-09-28 12:13
5299
Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. In this secondary listing, the issue price is HK$5...
2020-09-28 11:26
5134
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
* New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced * Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standar...
2020-09-28 06:00
2450
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
* New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced * Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standar...
2020-09-28 04:00
5416
Salonpas becomes Title Sponsor of Pulse Active's HCMC Marathon for the next 3 years
HO CHI MINH CITY, Vietnam, Sept. 25, 2020 /PRNewswire/ -- First held in 2013, HCMC Marathon is one of the largest and longest-standing marathon races in Vietnam, which has attracted over 51,000 runners across the world to participate in the last 7 years. The organizer of the race, Pulse Active is ...
2020-09-25 18:36
3673
Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- -Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menari...
2020-09-25 18:15
6513
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting
* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (CR) rate of 31.6%, median overall survival (mOS) of 19.7 months and an one-year overall survival (OS) rate of 55.5% in patients with relapsed or refractory extranodal natural killer /T cell lymphoma ...
2020-09-25 15:28
3798
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting
* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V mutant GIST * Avapritinib was generally well tolerated in Chinese GIST patients, consistent with the safety profile demonstrated in global studies SUZHOU, China, Sept. 25, 2020 /PRNewswire/ -- CSton...
2020-09-25 14:53
3823
New Centre for Medicines Research Report from Clarivate Indicates Drug Development Timelines are Shortest Since 2013
Pharmaceutical R&D industry report provides insights into what's behind decline in global NME outputs and reveals implications of decreased projected expenditures LONDON, Sept. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to acc...
2020-09-24 16:15
8757
Insilico releases Pandomics, AI-powered platform for Novel Therapeutic Target Discovery
A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel therapeutic targets HONG KONG, Sept. 23, 2020 /PRNewswire/ -- Insilico Medicine announces the official release ofPandomics - a part of the Pharma.ai AI ...
2020-09-23 22:00
2912
Genor Biopharma Announces Proposed Listing on the Main Board of SEHK
HONG KONG, Sept. 23, 2020 /PRNewswire/ -- JHBP (CY) Holdings Limited ("Genor Biopharma"or the "Company"; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, announced the proposed listing of its shares on the...
2020-09-23 12:00
2926
Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial
BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual ...
2020-09-22 20:53
2772
New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes
RALEIGH, North Carolina, Sept. 22, 2020 /PRNewswire/ -- According to new data presented at the 56th European Association for the Study of Diabetes (EASD) annual meeting, the GlycoMark blood test reflects beta-cell functional mass, which is important in identifying prediabetic individuals with the...
2020-09-22 19:00
1742
Week's Top Stories
Most Reposted
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
[Picked up by 331 media titles]
2024-05-23 10:00
SINGAPORE'S XSQUARE TECHNOLOGIES SECURES S$10.5M IN SERIES A FUNDING LED BY WAVEMAKER PARTNERS
[Picked up by 325 media titles]
2024-05-23 10:00Innomix and World Castle Association Pioneer LBMR project at Zhangbi Fortress
[Picked up by 321 media titles]
2024-05-20 13:48
Samsung Electronics Unveils Month-Long Celebration of Esports Events for Students in Southeast Asia
[Picked up by 320 media titles]
2024-05-21 08:00
Mitsui Bussan Secure Directions, Inc. launches Blackpanda IR Retainer, a cyber incident emergency response retainer service
[Picked up by 312 media titles]
2024-05-21 13:00
Most Read
Mitsui Bussan Secure Directions, Inc. launches Blackpanda IR Retainer, a cyber incident emergency response retainer service
2024-05-21 13:00
10312
Innomix and World Castle Association Pioneer LBMR project at Zhangbi Fortress
2024-05-20 13:48
9563
Samsung Electronics Unveils Month-Long Celebration of Esports Events for Students in Southeast Asia
2024-05-21 08:00
8757
Revolutionising Cardiac Care at Pantai Hospital Kuala Lumpur
2024-05-23 11:22
8451
Ferretti's first-quarter performance shines, with the new shipyard put into operation
2024-05-20 07:12
8132